D. Boral Capital Boosts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $3.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price raised by D. Boral Capital from $2.00 to $3.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. D. Boral Capital’s target price points to a potential upside of 62.16% from the company’s previous close.

Separately, HC Wainwright reissued a “buy” rating on shares of Lineage Cell Therapeutics in a research note on Friday. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $5.00.

Lineage Cell Therapeutics Trading Up 0.5%

LCTX opened at $1.85 on Friday. The stock has a fifty day moving average price of $1.72 and a 200 day moving average price of $1.65. Lineage Cell Therapeutics has a 1 year low of $0.37 and a 1 year high of $2.09. The stock has a market cap of $426.11 million, a price-to-earnings ratio of -6.61 and a beta of 1.74.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its earnings results on Thursday, March 5th. The company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.07. Lineage Cell Therapeutics had a negative return on equity of 74.10% and a negative net margin of 436.47%.The company had revenue of $6.61 million for the quarter, compared to analyst estimates of $1.96 million. As a group, sell-side analysts forecast that Lineage Cell Therapeutics will post -0.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of large investors have recently bought and sold shares of LCTX. XTX Topco Ltd acquired a new position in Lineage Cell Therapeutics during the fourth quarter worth $71,000. Jain Global LLC lifted its position in shares of Lineage Cell Therapeutics by 202.3% in the fourth quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after buying an additional 26,000 shares during the last quarter. ExodusPoint Capital Management LP acquired a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth about $303,000. Squarepoint Ops LLC bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth about $109,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth about $473,000. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.